Rybelsus vs. Compounded Oral Semaglutide: Understanding the Difference

Semaglutide belongs to a class of medications known as GLP-1 receptor agonists.

GLP-1 is a naturally occurring hormone involved in appetite, digestion, insulin secretion, and blood sugar regulation.

By activating GLP-1 receptors, semaglutide can help:

• Reduce appetite
• Increase feelings of fullness
• Reduce food intake
• Support blood sugar regulation

Semaglutide has been extensively studied in both injectable and oral forms.

The challenge with oral semaglutide isn't whether semaglutide can work. The challenge is getting enough of a peptide medication through the digestive system and into the bloodstream.

Semaglutide is a peptide.

Unlike many traditional pills, peptides aren't naturally well suited to oral delivery. The digestive system is designed to break peptides down, and relatively little semaglutide can normally cross from the gastrointestinal tract into the bloodstream.

That's why the formulation of an oral semaglutide medication matters.

Researchers have spent years studying ways to protect peptide medications during digestion and improve their absorption.

Rybelsus represents one approach to solving that problem.

Compounding pharmacies may prepare oral semaglutide using different formulations and dosage forms depending on the prescription and pharmacy.

Rybelsus is a commercially manufactured oral semaglutide tablet made by Novo Nordisk.

Unlike injectable semaglutide, Rybelsus is taken by mouth once daily.

Its formulation combines semaglutide with an absorption enhancer called SNAC, or sodium N-(8-[2-hydroxybenzoyl] amino) caprylate.

SNAC plays an important role in helping semaglutide survive and cross the stomach lining.

Research suggests that the interaction between semaglutide and SNAC creates a localized environment around the tablet that helps protect semaglutide from degradation while temporarily improving its absorption through the stomach.

In other words, Rybelsus isn't simply semaglutide compressed into a pill. Its delivery system is an important part of how the medication works.

Compounded oral semaglutide is a semaglutide-containing medication prepared by a qualified compounding pharmacy according to a prescription from a licensed healthcare provider when compounding is clinically appropriate and permitted under applicable requirements.

Depending on the pharmacy and prescription, compounded oral semaglutide may be prepared in forms such as:

• Oral tablets
• Sublingual preparations
• Orally disintegrating tablets (ODTs)
• Other pharmacy-specific formulations

The exact formulation can vary.

This is an important difference from Rybelsus.

“Compounded oral semaglutide” does not describe one universal formulation.

Two compounding pharmacies could potentially prepare oral semaglutide differently, using different concentrations, excipients, dosage forms, or administration instructions.

Patients should therefore follow the instructions provided for their specific prescription.

The easiest way to understand the difference is to look at how each treatment is prepared.

The biggest takeaway is that route of administration alone doesn't make two medications equivalent.

How semaglutide is formulated can affect how it is delivered and absorbed.

One of the most interesting things about Rybelsus is that much of its absorption occurs through the stomach, rather than farther along in the intestines.

SNAC helps create conditions around the tablet that protect semaglutide from enzymatic breakdown and facilitate absorption across the stomach lining.

Even with this technology, only a relatively small percentage of oral semaglutide reaches systemic circulation.

Clinical pharmacokinetic research has estimated oral semaglutide bioavailability at approximately 0.8% under recommended dosing conditions in the formulation studied.

This is why oral peptide medications can't be evaluated simply by comparing the number of milligrams written on the label.

How Rybelsus is taken can affect how much semaglutide is absorbed.

Research has found that factors such as water volume and the amount of time a patient waits before eating, drinking, or taking other oral medications can influence semaglutide exposure.

That's why Rybelsus comes with specific administration instructions.

Patients are generally instructed to take it on an empty stomach with a limited amount of plain water and then wait before eating, drinking, or taking other oral medications.

These instructions are connected to the way the formulation is absorbed.

This depends on the formulation.

A compounded tablet, sublingual preparation, or orally disintegrating formulation shouldn't automatically be assumed to behave exactly like Rybelsus.

The ingredients, dosage form, concentration, and intended route of absorption may differ.

There is extensive published clinical research on the commercially developed oral semaglutide formulation used in Rybelsus, including its pharmacokinetics and SNAC-based delivery system.

The evidence for an individual compounded oral formulation may not be identical.

That doesn't mean every compounded oral formulation should be treated the same way. It means patients and providers should understand which formulation is actually being prescribed and how the pharmacy intends it to be used.

Not necessarily.

This is one of the most important concepts to understand with oral semaglutide.

You cannot reliably compare two oral formulations based only on the number of milligrams they contain.

For example, a medication containing a larger amount of semaglutide isn't automatically “stronger” if a smaller proportion of that medication reaches the bloodstream.

Factors such as:

• Formulation
• Absorption technology
• Dosage form
• Timing around food
• Water intake
• Individual gastrointestinal differences

can all influence exposure.

The delivered dose and systemic exposure matter — not simply the amount of semaglutide present in the tablet or formulation.

For some patients, the biggest advantage is simple: no injections.

Someone may prefer an oral option because they:

• Dislike needles
• Don't want to perform weekly injections
• Prefer taking medication by mouth
• Want another treatment format to discuss with their provider

However, convenience depends on the individual.

A once-weekly injection may actually feel simpler to some patients than remembering a daily oral medication with specific administration instructions.

There isn't one format that's automatically best for everyone.

Oral semaglutide can produce many of the same types of gastrointestinal effects associated with injectable GLP-1 treatment.

These may include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal discomfort
• Reduced appetite

Side effects can be more noticeable when treatment begins or the dose increases.

A healthcare provider may adjust the treatment plan depending on how a patient responds.

Because compounded formulations can vary, patients should understand exactly what they have been prescribed.

Useful questions include:

• Which pharmacy prepares the medication?
• What dosage form am I receiving?
• What is the prescribed dose?
• How should I take it?
• Should it be swallowed, dissolved, or used another way?
• Should I take it with or without food?
• Are there restrictions around eating or drinking afterward?
• How should it be stored?
• How will my dose be adjusted?
• Who should I contact if I experience side effects?

Patients should follow the instructions accompanying their own prescription rather than applying Rybelsus instructions — or another patient's compounded-medication instructions — to a different formulation.

No.

Both may involve semaglutide, but Rybelsus is a specific commercially manufactured formulation with a studied SNAC-based absorption system. Compounded oral semaglutide can refer to different pharmacy-prepared formulations.

Compounded medications also follow a different regulatory pathway from commercially manufactured medications.

The practical takeaway for patients is straightforward:

Rybelsus and compounded oral semaglutide both provide ways of administering semaglutide without an injection, but they aren't identical products.

Rybelsus uses a specifically developed combination of semaglutide and SNAC to help the peptide medication survive and absorb through the stomach.

Compounded oral semaglutide may be prepared in different dosage forms and formulations depending on the pharmacy, prescription, and individual patient's treatment needs.

Neither option should be chosen based solely on the milligram number on the label.

Patients considering oral semaglutide should understand the formulation they're receiving, how it should be taken, and what to expect from treatment.

At Luma Meds, eligible patients are evaluated by a licensed healthcare provider who can determine whether an available treatment option may be appropriate based on their medical history, goals, and individual needs.